Alessandro Manzoni Hospital — Clinical Trial Site

50 Registered trials

30 Currently recruiting

Organisation

Alessandro Manzoni Hospital

Location

Lecco, Italy

Identifier

ORG-100031476

Address

Via Dell' Eremo 9, 23900, Italy

Departments

2409: S.C.Infectious diseases
4118:Oncologia
Anesthesia and Intensive Care
ASST Lecco - Ospedale A. Manzoni, Oncologia, via dell'Eremo 9/11
Cardiologia
Cardiology
Department of Oncology - Oncology unit
Dipartimento Area Neuroscienze
Dipartimento Area Oncologica
Dpt Nephrology and Dialysis
Hospital consultant cardiologist
Infectious diseases
Medical oncology
Nephrology, Dialysis and Renal Transplantation
Neurologia-Stroke Unit
Oncologia
Oncologia Medica
Oncologic Department
Oncologico
Oncology
Oncology Department
Ostetricia-Ginecologia
S.C. Cardiologia
S.C. DI CARDIOLOGIA
S.C. Oncologia
S.C. Oncologia Medica
U.O.C. Cardiologia
U.O.C. Nefrologia e Dialisi
U.O.S Emostasi e Trombosi
UO Cardiologia
UOC Neurology and Stroke Unit - Department of Neuroscoences
UOC Oncologia

Clinical trials at this site (50)

Search interface

Phase III study in mCRC patients with RAS/BRAF wild type tissue and RAS/BRAF mutated in LIquid BIopsy to compare in first-line therapy FOLFI… Recruiting

2024-517863-22-00 Study population consists in patients with a diagnosis 5 2024-12-01
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VE303 for Prevention of Recurrent Clostridioides difficile Infection: The Re… Recruiting

2022-502972-22-00 Clostridioides difficile infection. 5 2024-10-31
Trial to assess the safety and efficacy of high dose pulse intravenous corticosteroid therapy to treat patients with complicated/fulminant a… Recruiting

2023-504169-22-02 Severe cardiac inflammation 5 2024-07-31
SALVOVAR trial: A pragmatic randomized phase III trial to assess the utility of adjusting chemotherapy dose & dosing schedule with the SALVa… Recruiting

2023-508260-30-01 Patients with poor prognostic OVARian cancers based on 5 2024-07-30
N-PLUS Recruiting

2022-502559-69-01 advanced (FIGO stage IIIA, IIIB, IIIC, or IV of the 201 4 2024-07-04
A trial to learn if volrustomig is safe and efficacious in women and young adults with locally advanced cervical cancer. Recruiting

2023-504374-38-00 Locally advanced cervical cancer 5 2024-04-12
An international, multicenter, randomised, superiority phase III, open label, 2-arm study to investigate distant metastasis free survival wi… Recruiting

2022-501453-36-00 Breast cancer 5 2024-02-23
Akynzeo as antiemetic treatment in patients with endometrial cancer treated with taxane - platinum combination chemotherapy. NOEME study. Recruiting

2023-504150-35-00 Endometrial cancer 6 2024-02-21
A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaLuate the effIcacy and safety of abeLacimab… Recruiting

2023-503224-66-00 Atrial Fibrillation 5 2023-10-31
Tranexamic acid for hyperacute spontaneous IntraCerebral Haemorrhage (TICH-3) Recruiting

2022-500587-35-01 Stroke 5 2023-07-06
Roll Over Study for Patients Who Have Completed a Previous Oncology Study with Olaparib Recruiting

2024-512982-15-00 BRCA Mutated Ovarian Cancer Patients, Epithelian ovaria 5 2021-06-28
Phase II randomized trial comparing atezolizumab versus atezolizumab plus bevacizumab as first-line treatment in PD-L1 high advanced non-sm… Recruiting

2024-517200-10-00 Advanced non-small-cell lung cancer 4 2020-01-31
Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer After Platinum-Based Chemother… Ended

2024-511957-23-00 Recurrent or Persistent Endometrial Cancer 5 2025-01-03
Potential protective role of SGLT-2 inhibitors for chemotherapy-induced cardiotoxicity (PROTECT trial) Ended

2024-518611-18-00 Chemotherapy-induced cardiotoxicity in breast cancer 4 2024-12-03
A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascu… Ended

2022-502781-24-01 ASCVD - Atherosclerotic Cardiovascular Disease 5 2024-06-05
A Phase 3/3b, Randomized, Observer-blind, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Fluad and Fluad … Ended

2022-503004-24-00 Influenza virus 5 2023-10-20
LIBREXIA-AF A Phase 3 Active-controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants with Atrial Fibrillation Ended

2022-501419-15-00 Atrial Fibrillation 5 2023-08-23
A Phase 3 Placebo-controlled Study of Milvexian after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack Ended

2022-501176-26-00 Acute Ischemic Stroke and High-Risk Transient Ischemic 5 2023-08-04
A CLINICAL TRIAL TO CONFIRM THE EFFICACY OF OLAPARIB IN COMBINATION WITH BEVACIZUMAB, ADMINISTERED AS MAINTENANCE THERAPY AFTER A FRONTLINE … Ended

2022-502242-27-00 Patients with a confirmation of advanced, high grade ep 6 2023-06-16
An open-label, single-arm, Phase II, multinational, multicentre study to assess the efficacy and safety of 5 years of osimertinib in partici… Ended

2023-508740-21-00 Non-Small Cell Lung Cancer 4 2023-02-15
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable… Ended

2023-504195-14-00 PD-L1-negative metastatic triple-negative breast cancer 5 2022-08-31
Randomized phase III trial in MMR deficient endometrial cancer patients comparing chemotherapy alone versus Dostarlimab in first line advanc… Ended

2023-510097-14-00 Patients with MMR deficient relapse or advanced / metas 5 2022-04-15
Effectiveness and Safety of Sparsentan as treatment for Immunoglobulin A Nephropathy (IgAN) Ended

2023-505495-30-00 Immunoglobulin A Nephropathy (IgAN) 5 2019-02-01
Phase 2/3 Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer Ended

2022-502196-31-00 Advanced or Recurrent Endometrial Cancer 10 2023-08-21